Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Clinical Trials

Clinical Trials at The Methodist Hospital Research Institute

Search results...

Digestive System Diseases

Active and enrolling clinical trials for Digestive System Diseases are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Cirrhosis

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)

Salix: Rifaximin Soluble Solid Dispersion SSD Tablets for Decompensated Liver Cirrhosis
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or h...(read more)
Colon and Colorectal Cancer

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)
Diabetes Mellitus

EXSCEL
Study Status: Active/Enrolling
Investigator: Davies, Mark
Study Coordinator: Elliott, Dawn
Phone: 713-441-6536
Summary:This study will compare the impact of including exenatide once weekly as part of usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary cardiovascular ...(read more)
Hepatitis Infections

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)
Liver Diseases

Post-marketing registry of renal safety of HBV+ awaiting liver transplant
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:This registry will remain open for approximately 5 years. Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry. W...(read more)

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)
Liver Transplant

Salix: Rifaximin / Hepatic Encephalopathy study
Study Status: Active/Enrolling
Investigator: Monsour, Howard
Study Coordinator: Dorman, Susan
Phone: 713-441-6316
Summary:The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.(read more)